Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials
Basel-based biotech Nouscom has raised €67.5 million ($72.2 million) to bankroll its cancer vaccines as the eight-year-old company looks to capitalize on momentum in the field.
The Series C marks the biotech’s first venture investment in about six years; it last raised a $49 million Series B in late 2017.
“We’ve been careful not to over-commit ourselves on spending as we’ve gone and we’re very data-led, not hope-led, on these things,” operating and business chief Richard Davis told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.